CA
NZ
UK
AU
IND
US
The dividend is scheduled for distribution on September 1, 2026, rewarding those who hold shares until the record date of August 15, 2026. Investors may view this as a sign of the company's financial health, especially within a competitive market space.
Butterfly Network, Inc. (NYSE: BFLY) announced its latest quarterly results, showing revenue of $32.6 million, a 39% increase compared with the same period last year. The company’s strong revenue performance reflects continued adoption of its handheld ultrasound devices across a broadening patient base. This …
CareDx, Inc. (NASDAQ: CDNA) reported an impressive revenue increase of $132 million for the second quarter of 2026, marking a 52% boost compared to the same period last year. This growth aligns with analysts' expectations, as CareDx exceeded consensus estimates of $0.24 per share, …
Ceribell, Inc. has undertaken significant changes to its Board of Directors, augmenting its leadership with two new appointments, effective July 28, 2026. This move expands the board from seven to nine members, aimed at enhancing its governance structure and balancing membership across different classes …
Cerus Corporation (NASDAQ: CERS) reported a revenue increase of 5% year-over-year for the second quarter of 2026, amounting to $63.3 million compared to $60.1 million during the same period last year. This growth is supported by a notable surge in product revenue, which alone …
Cigna Delivers Strong Quarterly Results
Contineum Therapeutics (NASDAQ: CTNM) announced a second‑quarter net loss of $15.2 million, an improvement over the loss of $16.0 million recorded a year earlier. Cash and marketable securities stand at $236.6 million, providing a solid liquidity cushion that extends the company’s runway well into …
Brainstorm Cell Therapeutics Inc. has appointed Peter Pitts as Executive Chairman and Chief Strategic Regulatory Officer, granting him an option to purchase 900,000 shares. This strategic adjustment may imply a focused effort on regulatory alignment as the company navigates its healthcare initiatives.Key HighlightsPeter Pitts …
Annexon, Inc. has entered into a strategic credit facility agreement totaling $200 million, aiming to bolster its operational capacity. This non-dilutive funding will support the advancement of its neuroinflammatory therapies, enhancing investor confidence as the company progresses toward potential commercialization.Key HighlightsAnnexon has secured a …
Avanos Medical, Inc. has secured a substantial $675 million credit facility as part of its recent merger with A-AV Holdco, which is linked to American Industrial Partners. This agreement positions Avanos for enhanced financial flexibility moving forward. The facility provides immediate funds that can …
Please wait processing your request...